<DOC>
	<DOCNO>NCT03076957</DOCNO>
	<brief_summary>The purpose open-label , dose-escalation phase I trial evaluate safety , tolerability pharmacokinetic profile assess efficacy CKD-516 Tablet Combination Irinotecan inj . Patients Previously Treated Advanced Colorectal Cancer</brief_summary>
	<brief_title>A Phase 1/2a Study Assess Safety Efficacy CKD-516 Tab . Combination With Irinotecan Inj .</brief_title>
	<detailed_description>CKD-516 tab . combination Irinotecan inj . ( 1cycle=14days )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>1 . Male female patient age 19 year old 2 . Patients fail exist anticancer therapy 3 . ECOG performance status ≤ 1 4 . Life expectancy ≥ 12 week 5 . Adequate hematological , hepatic renal function : 6 . Patients give write informed consent voluntarily 1 . Prior systemic chemo , radiochemo , radio , immuno , hormonal and/or biological therapy within 2 week study participation ( case nitrosoureas and/or mitomycin , within 6 week study participation ) 2 . Patients receive major surgery within 4 week study participation ( case VATS and/or ONC surgery , within 2 week study participation ) 3 . Symptomatic CNS metastasis ( patient radiologically neurologically stable metastasis corticosteroid least 4 week able participate trial . ) 4 . NYHA class III IV heart failure , uncontrolled hypertension ( SBP/DBP &gt; 140/90 mm Hg ) , clinically significant cardiovascular abnormality investigator 's discretion ( e.g. , LVEF &lt; 50 % , clinically significant cardiac wall abnormality cardiac muscle damage ) 5 . Acute coronary syndrome ( unstable angina myocardial infarction ) within 6 month 6 . Uncontrolled arrhythmia 7 . Significant cerebrovascular disease include stroke within 6 month 8 . Significant vascular disease include aortic aneurysm require treatment peripheral arterial disease 9 . Patients know active hepatitis , HIV infection , uncontrolled infectious disease 10 . Patients receive IP mouth history clinically significant gastrointestinal disorder impede administration , transit absorption IP 11 . A history severe drug hypersensitivity hypersensitivity analog IP 12 . Pregnancy breastfeed 13 . Women childbearing potential ( WOCBP ) men unwilling use adequate contraception abstinent trial least 3 month end treatment 14 . Patients receive investigational product use investigational device within 3 week participation 15 . Patients participate trial investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>